• AAPL 169.89
  • TSLA 170.18
  • AMZN 173.67
  • MSFT 399.04
  • INTC 35.11
  • EURUSD 1.0745
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. NASDAQ /
  3. ALDX.NASDAQ

Aldeyra The (ALDX NASDAQ) stock market data APIs

$3.9 -0.04(-1%) as of April 25, 2024

Aldeyra The Financial Data Overview

3.94
3.9
-
4.045
3.86
1.42-11.97
234 M
59 415 K
0
-0.08
1.525
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'ALDX',
Type: 'Common Stock',
Name: 'Aldeyra The',
Exchange: 'NASDAQ',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
ISIN: NULL,
CUSIP: NULL,
CIK: '1341235',
EmployerIdNumber: '20-1968197',
FiscalYearEnd: 'December',
IPODate: '2014-05-02',
InternationalDomestic: 'Domestic',
Sector: 'Healthcare',
Industry: 'Biotechnology',
HomeCategory: 'Domestic',
IsDelisted: false,
}

Aldeyra The Fundamental Data is available in our Financial Data APIs

  • Net Revenue 0
  • EBITDA -42 531 304
  • Earnings Per Share -0.64
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Aldeyra The Earnings via APIs

  • Latest Release 2024-03-28
  • EPS/Forecast -0.14

Get Aldeyra The End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Aldeyra The latest news via APIs

Aldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of RASP Platform in Systemic and Retinal Inflammatory Diseases

(Graphic: Aldeyra Therapeutics) Based on positive biomarker results observed in adult cohort of Phase 2 clinical trial of ADX-629 in Sjögren-Larsson Syndrome, proposed expansion to include pediatric...

Aldeyra Therapeutics Announces Statistically and Clinically Significant Improvement from Baseline in Phase 2 Clinical Trial of ADX‑629 in Patients with Atopic Dermatitis

Statistically significant improvement from baseline observed in investigator-assessed Eczema Area and Severity Index (EASI, p=0.0006) and Investigator Global Assessment (IGA, p<0.0001) EASI 75% improv...
Do you have any questions?
support@eodhistoricaldata.com